Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Accounts Payables: 2010-2025

Historic Accounts Payables for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $17.7 million.

  • Arrowhead Pharmaceuticals' Accounts Payables rose 55.20% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year increase of 55.20%. This contributed to the annual value of $17.7 million for FY2025, which is 55.20% up from last year.
  • According to the latest figures from FY2025, Arrowhead Pharmaceuticals' Accounts Payables is $17.7 million, which was up 55.20% from $11.4 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Accounts Payables registered a high of $35.9 million during FY2023, and its lowest value of $2.9 million during FY2022.
  • Moreover, its 3-year median value for Accounts Payables was $17.7 million (2025), whereas its average is $21.6 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Accounts Payables slumped by 69.67% in 2022 and then skyrocketed by 1,150.56% in 2023.
  • Arrowhead Pharmaceuticals' Accounts Payables (Yearly) stood at $9.5 million in 2021, then plummeted by 69.67% to $2.9 million in 2022, then surged by 1,150.56% to $35.9 million in 2023, then tumbled by 68.25% to $11.4 million in 2024, then surged by 55.20% to $17.7 million in 2025.